newsfilter
← Latest News
Business Wire·

iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium

iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic, in vivo targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced that data from the ongoing